Answers are grounded in this paper and cite their sources.
Upregulation of CCNE1 by palbociclib confers resistance to palbociclib, which can be reverted by INK128. A, Relative mRNA levels of CCND1 and CCNE1 in Cal27 treated with INK128 and/or palbociclib for 24 hours. B, Signaling change with INK128 and/or palbociclib treatment. Cal27 cells were treated with 50 nmol/L of INK128, 1 µmol/L of palbociclib, or both for 48 hours after serum starvation overnight and were analyzed for indicated proteins by Western blotting. C, Cell viability of Cal27 cells treated with palbociclib. Comparison of wt, overexpressing CCND1, CCNE1, and both (mean ± SEM, n = 3). D, Cell viability of Cal27 cells treated with palbociclib. Comparison of wt, overexpressing CCNE1, and CCNE1+INK128 treatment (mean ± SEM, n = 3). E, eIF4G binding assay with INK128 and/or palbociclib treatment for CCNE1. Proteins from each treated Cal27 were immunoprecipitated by eIF4G. RNA was extracted from the IP product, and expression of CCNE1 was determined by qPCR (mean ± SEM, n = 3). F, eIF4G binding assay with INK128 and/or palbociclib treatment for CCND1. Proteins from each treated Cal27 were immunoprecipitated by eIF4G. RNA was extracted from the IP product, and expression of CCND1 was determined by qPCR (mean ± SEM, n = 3). G, Schema for CCND1 and CCNE1 mRNA translation. mTORC1 phosphorylates 4EBP1 and promotes mRNA translation. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, nonsignificant. P value was determined using one-way ANOVA with the Tukey post hoc test in A. P value was determined using two-way ANOVA with the Tukey post hoc test in E and F. (Created with BioRender.com.)
No takes yet. Share an insight, caveat, or question.
Goto et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: